SCHEMBL5541594

SCHEMBL5541594

[CH2]CCCCN1CCN(C(=O)OCc2ccc(F)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 5/20 0.55
DRD4 P21917 5/20 0.55
HRH2 P25021 4/20 0.55
HTR1A P08908 4/20 0.55
HTR2A P28223 4/20 0.55
OPRM1 P35372 4/20 0.55
CACNA1F O60840 3/20 0.55
ADORA3 P0DMS8 3/20 0.55
DRD5 P21918 3/20 0.55
ADRA1D P25100 3/20 0.55
HTR7 P34969 3/20 0.55
ADRA1A P35348 3/20 0.55
ADRA1B P35368 3/20 0.55
DRD3 P35462 3/20 0.55
HTR6 P50406 3/20 0.55
CACNA1D Q01668 3/20 0.55
SLC6A3 Q01959 3/20 0.55
CACNA1S Q13698 3/20 0.55
CACNA1C Q13936 3/20 0.55
DRD2 P14416 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545410 0.99 HRH1 (0.54) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5544486 0.96 HRH1 (0.56) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5536473 0.91 HRH2 (0.52) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5540188 0.88 HRH2 (0.52) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5542172 0.87 NPSR1 (0.56) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5543858 0.87 SIGMAR1 (0.46) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5544670 0.87 GRIN2B (0.51) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL27610472 0.86 NPSR1 (0.54) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5540479 0.86 SIGMAR1 (0.45) HRH1DRD4HRH2HTR1AHTR2A
SCHEMBL5543766 0.85 HRH1 (0.53) HRH1DRD4HRH2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HRH1 668/4885DRD4 368/4885HRH2 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.